Adoptive T-cell therapy for Hodgkin lymphoma

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• CAR T-cell therapy is FDA-approved for B-cell lymphomas but lags in classic Hodgkin lymphoma (cHL) development.
• Adoptive T-cell therapies are emerging as potential treatments for cHL.

Purpose of the Study:

• To review the current landscape of clinical trials for adoptive immunotherapy in cHL.
• To identify challenges and novel strategies for advancing CAR T-cell therapy in cHL.

Main Methods:

• Review of early clinical trials involving Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells for cHL.
• Investigation of CD19 and CD123 CAR T cells targeting the cHL tumor microenvironment.

Main Results:

• Epstein-Barr virus-specific T cells and CD30 CAR T cells have shown significant clinical responses in early cHL trials.
• CAR T cells targeting the immunosuppressive tumor microenvironment are under investigation for cHL.

Conclusions:

• Adoptive immunotherapy, particularly CAR T-cell therapy, holds potential for cHL treatment.
• Further research is needed to overcome challenges and optimize CAR T-cell therapy development for cHL.